GlassScriptPhysician profile
Shetal Shah
NPI 1295066918
$3,917.57
in general payments reported to CMS, 2019-2025
20 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $177 · 2021: $224 · 2022: $383 · 2023: $786 · 2024: $969 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,049.95 | 2022-2025 | Clareon, Tryptyr, Simbrinza |
| Abbvie INC. | $918.97 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Oyster Point Pharma, INC. | $488.62 | 2022-2025 | Tyrvaya |
| Eyevance Pharmaceuticals LLC | $262.46 | 2019-2022 | |
| Allergan, INC. | $250.28 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $136.32 | 2024-2025 | Xdemvy |
| Rxsight INC | $130.96 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece |
| Harrow Eye, LLC | $117.32 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $113.28 | 2023-2025 | Xiidra, Miebo |
| Amgen INC. | $65.83 | 2024-2025 | Tepezza |
| Shire North American Group INC | $64.01 | 2019 | |
| Biotissue Holdings INC. | $63.99 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $56.01 | 2021 | |
| Horizon Therapeutics Plc | $42.99 | 2023 | Tepezza |
| Astellas Pharma US INC | $29.98 | 2025 | Izervay |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $28.46 | 2022 | |
| Sun Pharmaceutical Industries INC. | $27.66 | 2020 | |
| Dompe US, INC. | $26.64 | 2024 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.78 | 2019 | |
| Ocular Therapeutix, INC. | $18.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shetal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.